MesoCoat Engages EWI to Accelerate Manufacturing Scale-Up of CermaClad Clad Pipes

Abakan Inc. ("Abakan"), an emerging leader in the advanced coatings and metal formulations markets, today announced that its subsidiary MesoCoat has engaged EWI, the world leader in welding and allied technologies, to accelerate manufacturing scale-up of its CermaClad™ clad pipes.

EWI will bring its world-renowned expertise to the project and provide simulation and controls development services to support the development of manufacturing process specifications and non-destructive testing procedures, followed by bimetallic pipe welding and joining process qualification.

"This project is the latest in a series of initiatives aimed at engaging leading experts and organizations around the world in the surface engineering and materials science industry," said Robert Miller, CEO of Abakan Inc. "Last month, we added Dr. Damian Kotecki to our team, who is considered by many to be the leading authority on welding, while EWI is North America's top developer of materials joining and additive manufacturing technology. Engaging EWI to support development of the CermaClad™ large-area fusion cladding technology enables us to tap into their incredible talent pool and knowledge base to help Abakan continue to be on the forefront of science and innovation for the foreseeable future."

The CermaClad™ high-speed large-area clad pipe technology produces a superior metallurgical clad pipe product for the oil and gas industry, where the availability of metallurgical clad pipes and the associated lead time have been a barrier to the development of oil and gas reserves around the world.

The technology uses a high intensity plasma light source – a "mini-sun" -- to rapidly fuse anti-corrosion and anti-wear materials to large areas of steel, including pipes. MesoCoat's process offers 40 times higher productivity compared to current metallurgical cladding technologies and it enables a three to six times longer life for metal assets and improved metallurgical and mechanical properties at the lowest lifecycle cost. CermaClad™ offers on-time delivery and up to 80 percent reduction in lead times for seamless, metallurgically clad pipes at costs lower than those of competing alternatives.

EWI develops and applies technology innovation within the manufacturing industry. Since the early 1980s, the company has helped manufacturers in the aerospace, automotive, government/defense, heavy manufacturing, consumer products, light industrial, energy and rail industry sectors improve operational efficiencies through the development of innovative materials and associated technologies.

EWI also operates a number of centers and consortia that act as hubs for the advancement of specific technologies and industries, all of which are designed to improve public-private collaboration, strengthen U.S. manufacturing supply chains and make U.S. manufacturers more competitive on a global scale. The consortia include the Additive Manufacturing Consortium, EWI Defense Center, EWI Nuclear Fabrication Center, EWI Rail Manufacturing Technology Center and EWI Forming Center.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abakan Inc.. (2019, February 09). MesoCoat Engages EWI to Accelerate Manufacturing Scale-Up of CermaClad Clad Pipes. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=36428.

  • MLA

    Abakan Inc.. "MesoCoat Engages EWI to Accelerate Manufacturing Scale-Up of CermaClad Clad Pipes". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=36428>.

  • Chicago

    Abakan Inc.. "MesoCoat Engages EWI to Accelerate Manufacturing Scale-Up of CermaClad Clad Pipes". AZoM. https://www.azom.com/news.aspx?newsID=36428. (accessed November 21, 2024).

  • Harvard

    Abakan Inc.. 2019. MesoCoat Engages EWI to Accelerate Manufacturing Scale-Up of CermaClad Clad Pipes. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=36428.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.